The Hospital Readmissions Reduction Program (HRRP) established in the Affordable Care Act has further focused hospital efforts to improve quality and patient outcomes.
In a Medicare Payment Advisory Commission (MedPAC) report to Congress, coronary artery bypass graft (CABG) surgery was ranked as having the highest potentially preventable readmission rate. Volume flow measurement provides an objective, intraoperative assessment of the quality and patency of grafts and could help prevent costly re-operations and readmissions.
Transonic’s Optima 354C Flowmeter, with automated Graft Patency Assessment capability, evaluates mean flow and flow waveform characteristics to provide a real-time assessment of graft patency.
An Introduction to Trasonic's CABG Patency Assessment program
We are looking to partner with hospitals in pursuit of their strategic initiatives to standardize processes, control risk and reduce preventable readmissions with the introduction of a CABG Patency Assessment program. The foundation for the program is years of working closely with surgeons to understand flow and the development of the Optima 354C Flowmeter.
Reducing overall readmissions is a complex endeavor that touches many areas of patient care and hospital operations. In the case of CABG surgery, measuring flow intraoperatively is a direct, targeted and inexpensive step that can help tip the scale in the hospital’s favor for CABG success.
The Transonic Patency Assessment program expresses our confidence that complications stemming from graft-related issues are far less likely if the graft meets Transonic’s patency protocol standards at the completion of the surgery.
In fact, we are so confident that intraoperative flow measurement will improve outcomes, reduce costs associated with re-operations and readmissions and contribute to hospital quality goals, that the program provides credits for future meter usage should a patient be readmitted within 30 days*.
To learn more about this innovative partnership program, simply click here.